Cannabis trade body will also focus on clinical trials
The Centre for Medicinal Cannabis (CMC) has .
The CMC, which describes itself as an industry advocacy group and think tank, said its plans to “actively engage industry players” in clinical trials focusing on childhood epilepsy and “all other non-paediatric potential deployments of cannabis, would help boost learning and accelerate patient access to medicines, as well as market authorisation for cannabis-based medical products.
The announcement comes after Dame Sally Davies, chief medical officer for England, told MPs that clinical trials were the only way to get medical cannabis products licenced; she called on industry to take the lead and also to fund them.
The CMC said it wanted to expand its original remit — which focused on policy, research and advocacy — to now include accelerating clinical trials, shaping future regulation of products and to promote clinical education.
Making the announcement, Steve Moore, its strategic counsel, said: “This immediately strengthens the CMC’s capacity to shape the future of medicinal cannabis in the UK.
“We have adopted a ‘whole equation’ approach and will now be able to contribute across the spectrum of public policy, clinical research, medical education and public advocacy across all areas of regulation and law governing both high-THC unlicensed medicines … and cannabidiol products available without prescription to UK consumers.”
Citation: The Salvadore DOI: 10.1211/PJ.2019.20206418
Recommended from Pharmaceutical Press
All you need to know about prescribing or administering drugs via enteral feeding tubes. Over 400 drug monographs as well as facts to inform clinical decision making.£54.00
Now in its twelfth edition, Stockley’s Drug Interactions is still the most comprehensive and authoritative international source of drug interaction information.£240.00
Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.£54.00
Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.£40.00
An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.£54.00